Core Viewpoint - The recent rise in domestic insurance stocks is attributed to the issuance of guidelines by the Financial Regulatory Bureau aimed at promoting the high-quality development of health insurance, which includes the reintroduction of participating long-term health insurance products after a 22-year hiatus [1] Group 1: Stock Performance - Domestic insurance stocks collectively rose, with notable increases: Xinhua Insurance up 3.11% to HKD 48.46, China Pacific Insurance up 3.02% to HKD 31.4, China Life Insurance up 3.02% to HKD 22.52, and Ping An Insurance up 1.03% to HKD 54.05 [1] Group 2: Regulatory Changes - The Financial Regulatory Bureau issued guidelines that outline the overall direction and phased goals for the development of health insurance, specifically supporting well-rated insurance companies in launching participating long-term health insurance products [1] Group 3: Market Implications - The reintroduction of participating health insurance is expected to enhance product attractiveness and stimulate growth potential in the health insurance market, especially in the context of continuously declining preset interest rates [1] - The guidelines are anticipated to enrich product offerings and improve the appeal of "product + service," potentially leading to a new wave of development opportunities for various health insurance types, while also reducing risk related to interest rate spreads for insurance companies, thereby benefiting profitability and valuation levels [1]

Core Viewpoint - The recent rise in Chinese insurance stocks is attributed to the release of regulatory guidelines aimed at promoting the high-quality development of health insurance, which includes the reintroduction of participating health insurance products after a 22-year hiatus [1][1][1] Group 1: Stock Performance - Chinese insurance stocks collectively experienced gains, with notable increases: Xinhua Insurance rose by 3.11% to HKD 48.46, China Pacific Insurance increased by 3.02% to HKD 31.4, China Life Insurance also rose by 3.02% to HKD 22.52, and Ping An Insurance saw a 1.03% increase to HKD 54.05 [1][1][1] Group 2: Regulatory Developments - The Financial Regulatory Bureau issued guidelines that outline the overall direction and phased goals for the development of health insurance, specifically supporting well-rated insurance companies in launching participating long-term health insurance products [1][1][1] - The reintroduction of participating health insurance products is expected to enhance product attractiveness and stimulate growth in the health insurance market [1][1][1] Group 3: Market Implications - Dongwu Securities noted that the return of participating health insurance products could help improve product appeal and further unlock the growth potential of the health insurance market, especially in the context of declining preset interest rates [1][1][1] - Kaiyuan Securities highlighted that the new guidelines are likely to enrich product offerings and enhance the attractiveness of "product + service" combinations, potentially leading to a new wave of development opportunities for various health insurance types, while also reducing risk related to interest rate spreads for insurance companies [1][1][1]

Core Viewpoint - The average dividend realization rate for the life insurance industry in 2024 is 61.7%, an increase of 11 percentage points year-on-year, indicating improvements in the management and expectation guidance of participating insurance products [3][4]. Dividend Realization Rate Analysis - As of September 10, 2024, 76 life insurance companies reported 3,357 participating insurance products, with 12 products having a realization rate of zero, 2,726 products (81.2%) below 100%, 256 products (7.6%) achieving 100%, and 363 products (10.8%) exceeding 100% [3][4]. - The realization rate reflects the insurance company's ability to fulfill non-guaranteed dividends, serving as a key indicator of investment management effectiveness and operational transparency [4]. Improving Dividend Realization Rates - The National Financial Regulatory Administration issued a notice on August 2, 2024, emphasizing the need for insurance companies to balance demonstration benefits with realization rates [6]. - The relationship between demonstration benefits and realization rates is crucial, where demonstration benefits are based on hypothetical investment scenarios, while realization rates reflect actual performance [8][9]. - To enhance realization rates, companies must set reasonable demonstration rates and improve investment capabilities, especially for already sold policies [11]. Evaluation Criteria for Life Insurance Companies - Long-term assessment of realization rates should consider historical data, stability of dividend policies, and the company's long-term investment returns [13]. - Companies should maintain a safe solvency margin and healthy risk ratings, focusing on those with stable operations [13]. - Currently, 42 companies meet the criteria set by "13精," with New China Life Insurance leading in average realization rates for 2024 [14]. New China Life Insurance Performance - New China Life Insurance reported an average realization rate of 156.1% over the past five years, ranking first among 27 companies [15]. - In 2024, 80 participating insurance products were disclosed, with 63 products achieving or exceeding a 100% realization rate, reflecting strong investment return capabilities [17]. - The company has shown excellent long-term investment returns, with an average total investment return rate of 5.1% from 2015 to 2024, and total assets reaching 1.78 trillion yuan, indicating robust market validation of its investment capabilities [17][18].

Core Insights - Xinhua Insurance's stock price increased by 2.12% on October 10, reaching 63.07 CNY per share, with a total market capitalization of 196.75 billion CNY [1] - The company has seen a year-to-date stock price increase of 32.19%, with a 6.48% rise over the past five trading days [1] Financial Performance - For the first half of 2025, Xinhua Insurance reported a net profit of 14.799 billion CNY, representing a year-on-year growth of 33.53% [2] - The company had zero operating revenue for the same period [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 15.88% to 61,000, while the average number of circulating shares per person increased by 18.96% to 34,325 shares [2] - Cumulative cash dividends since the A-share listing amount to 35.939 billion CNY, with 13.913 billion CNY distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 60.5095 million shares, an increase of 6.6977 million shares from the previous period [3] - Huatai-PB CSI 300 ETF is the tenth-largest circulating shareholder, holding 14.9041 million shares, up by 1.1914 million shares [3]

Core Viewpoint - The release of the "Guiding Opinions on Promoting the High-Quality Development of Health Insurance" by the China Banking and Insurance Regulatory Commission (CBIRC) is expected to benefit the long-term development of health insurance, improving the investment ecology for insurance funds in a persistently low interest rate environment. The implementation of new standards is anticipated to enhance the profitability elasticity of insurance companies as stock holdings increase [1][2]. Group 1: Policy Highlights - The policy supports the development of dividend-type long-term health insurance, allowing well-rated insurance companies to engage in this business, which has seen improvements in pricing standards and consumer protection [3]. - The introduction of "personal account-style long-term medical insurance" emphasizes the accumulation of personal funds to cover out-of-pocket expenses, aiming to alleviate financial pressure on residents' medical insurance funds [4]. - The policy encourages the development of commercial insurance payment functions to reduce the burden on basic medical insurance and support the innovation of drugs and medical devices [5]. Group 2: Industry Development Opportunities - The policy promotes data sharing and collaboration across industries to enhance the efficiency of commercial health insurance claims [6]. - Support is provided for health insurance companies to integrate health management services into their products, potentially creating a competitive advantage in the market [7][8]. - New opportunities are anticipated for long-term care insurance, with provisions for converting life insurance benefits into care expenses and addressing various care needs [9].

A 股证券代码：601336 A 股证券简称：新华保险 公告编号：2025-054 号 H 股证券代码： 01336 H 股证券简称：新华保险 新华人寿保险股份有限公司 关于召开 2025 年第三次临时股东大会的通知 新华人寿保险股份有限公司董事会及全体董事保证本公告内容不存在任 何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2025 年第三次临时股东大会（以下简称"本次股东大会"或"股东大会"） 股东大会召开日期：2025年10月31日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：新华人寿保险股份有限公司（以下简称"本公司"或 "公司"）董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 10 月 31 日 14 点 30 分 召开地点：北京市朝阳区建国门外大街甲 12 号新华保险大厦 21 层 (五) 网络投票的系统、起止日期和投票时间。 ...

Core Viewpoint - The article discusses the analysis of the embedded value changes of listed life insurance companies for the first half of 2025, highlighting a 7.7% growth in embedded value, driven by various factors including expected returns and new business value creation [2][14]. Summary by Sections Embedded Value Changes - The embedded value of listed life insurance companies increased by 7.7% in the first half of 2025, with the expected return on the initial embedded value contributing 2.8%, new business value creation contributing 2.6%, investment return differences contributing 1.4%, and operational experience deviations contributing 0.83% [14][26]. ROEV Analysis - The overall Return on Embedded Value (ROEV) for listed life insurance companies was 6.3%, a decrease of 0.5 percentage points year-on-year. Companies like China Life, Ping An Life, and Taiping Life saw a decline in ROEV, while New China Life, AIA, and Sunshine Life experienced improvements [29][30]. Factors Influencing Embedded Value - The factors influencing the embedded value changes are ranked as follows: expected return on embedded value, new business value creation, investment return differences, operational experience deviations, and changes in assumptions and models [16][18]. Detailed Breakdown of Influencing Factors - **Expected Return on Embedded Value**: Averaged 2.8%, down 0.5 percentage points year-on-year, with most companies (except AIA) showing a decline [18]. - **New Business Value Creation**: Contributed 2.56%, down 0.2 percentage points year-on-year, with some companies like Ping An Life and New China Life showing improvements while others declined [18]. - **Operational Experience Deviations**: Averaged 0.83%, up 0.1 percentage points year-on-year, indicating positive impacts from actual operational experiences [23]. - **Investment Return Differences**: Averaged 1.4%, up 0.5 percentage points year-on-year, with most companies reporting positive deviations [26]. Company-Specific Insights - Sunshine Life reported the highest ROEV at 11.1%, followed by AIA at 8.6% and Ping An Life at 7.5% [30].

智通财经APP讯，新华保险(01336)发布公告，该公司将于2025年12月12日派发中期股息每股0.67元人民 币。 ...

新华保险（601336）(01336)发布公告，该公司将于2025年12月12日派发中期股息每股0.67元人民币。 ...

新华人寿保险股份有限公司 2025 年第三次临时股东大会 会议材料 二〇二五年十月九日 北京 1/39 新华人寿保险股份有限公司 2025 年第三次临时股东大会议程 会 议 时 间 ：2025 年 10 月 31 日（星期五）下午 14 点 30 分 会 议 地 点 ：北京市朝阳区建国门外大街甲 12 号新华保险大厦 21 层 会议召集人：新华人寿保险股份有限公司董事会 一、宣布会议开始及会议议程 二、审议议案 （一）普通决议事项 1. 关于 2025 年度中期利润分配方案的议案 （二）特别决议事项 2. 关于修订《公司章程》及撤销监事会的议案 3. 关于修订《股东大会议事规则》的议案 4. 关于修订《董事会议事规则》的议案 三、回答股东提问 四、宣布出席会议股东及股东代理人人数、代表股份数 六、休会、统计现场表决结果 七、宣布现场表决结果 议案一 关于 2025 年度中期利润分配方案的议案 各位股东： 经德勤华永会计师事务所（特殊普通合伙）审阅，公司 2025 年中期母公 司财务报表净利润为 143.33 亿元（人民币，下同），合并财务报表归属于母公 司股东的净利润为 147.99 亿元。截至 2025 年 ...